The high level of commercial success experienced by the key companies in the
cancer therapy market makes the market extremely attractive to drug
developers. Treatment of cancer has shifted toward a more focused attack on
the disease with targeted therapies. However, austerity packages imposed could
see slower commercial growth and larger generic erosion of key brands.
Features and benefits
Analysis of the top 20 oncology therapy brands in the seven major markets
In depth analysis of the factors influencing the top 20 oncology brands in
individual countries of the seven major markets
Sales forecasts for the top 20 cancer therapy brands from 2011 to 2021
Brand dynamics and assessment of the top 5 cancer brands in the seven
The total sales of the top 20 cancer therapy brands in the seven major markets
was $37.2bn in 2011, with targeted therapies representing 74% of those sales.
However, the oncology market is fragmenting as developers focus on niche
subsets of patients with specific genetic mutations, making it harder for
drugs to reach blockbuster status.
Targeted therapies dominated the market, and will increase their share of the
top 20 as patent expiries continue to impact sales of other drug classes.
Generic erosion of multiple key brands in the cytotoxic class will be the key
driver in decreasing its share of the top 20 branded sales from 17% in 2011 to
10% in 2021.
Avastin did not achieve the top position in any of the individual markets, the
US, Japan, or 5EU, due to a combination of US indication removal,
cost-conservative EU markets, strong antihormonal sales in Japan, and tough
Swiss Franc exchange rates.
Your key questions answered
Quantify the performance of each of the top 20 cancer therapy brands in
the seven major markets in 2011 and 2021.
Acquire an account of top-selling cancer brand dynamics and the events
that drive and limit their market growth.
The report is accompanied by a PowerPoint presentation and Excel
deliverable showing full top 20 forecasts for the US, Japan and 5EU.
Table of Contents
Table of Contents
Strategic scoping and focus
Datamonitor key findings
Market definition for cancer therapies
Antihormonal therapies by ATC class
Cytotoxic therapies by ATC class
Targeted therapies by ATC class
Forecast methodology and assumptions
Additional forecast methodology
MARKET OVERVIEW AND CONTEXT
Cancer therapy brands included in this report
Seven major markets top 20 oncology therapy brands
Targeted therapies will continue to control the seven major markets top
US top 20 oncology therapy brands
Cytotoxic brands lose out following patent expiries as targeted
therapies fragment the market
Japan top 20 oncology therapy brands
Patent expiries are likely to become more significant over the forecast
Five major EU markets top 20 oncology therapy brands
Economic constraints limit sales growth of targeted therapies
Avastin maintains overall leading position despite not topping any of
the markets in 2011
Figure: Unevented and evented company-reported sales-based forecasts
Figure: Sales of the top 20 cancer therapy brands in the seven major
markets, by drug class ($m), 2011 and 2021
Figure: Sales of the top 20 cancer therapy brands in the US, by drug class
($m), 2011 and 2021
Figure: Sales of the top 20 cancer therapy brands in Japan, by drug class
($m), 2011 and 2021
Figure: Sales of the top 20 cancer therapy brands in the five major EU
markets by drug class ($m), 2011 and 2021
Figure: Key branded drug sales, 2011 - 21
Figure: Avastin sales, by market ($m), 2011 - 21
Figure: Rituxan sales, by market ($m), 2011 - 21
Figure: Herceptin sales, by market ($m), 2011 - 21
Figure: Gleevec sales, by market ($m), 2011 - 21
Figure: Revlimid sales, by market ($m), 2011 - 21
Figure: Erbitux sales, by market ($m), 2011 - 21
Figure: Lupron sales, by market ($m), 2011 - 21
Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011 published by Datamonitor in September 3, 2012. This report consists of Pages: 47 and the price starts from US $ 11400.